Clinical Trial Update: Autologous Mesenchymal Stromal Cells for Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing autologous mesenchymal stromal cells in relapsing-remitting and secondary progressive multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Autologous mesenchymal stromal cells (mesenchymal stromal cells)

Snippet

Sponsor: Banc de Sang i Teixits | Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1, Phase 2 | Status: COMPLETED